Exonate

Executive Summary

Exonate is a UK-based biotechnology company pioneering non-invasive, topical eye drop treatments for retinal vascular diseases such as diabetic eye disease and wet age-related macular degeneration (AMD). Leveraging proprietary SRPK1 inhibitors, the company's approach targets VEGF splicing to address the underlying pathology of these conditions, differentiating itself from standard-of-care intraocular injections. By potentially replacing invasive injections with a self-administered eye drop, Exonate aims to improve patient compliance, reduce treatment burden, and expand access to therapy. The company is privately held and headquartered in Cambridge, United Kingdom, focusing on small-molecule therapeutics that could transform the management of leading causes of vision loss. While Exonate's pipeline is in early stages, its topical delivery platform represents a significant innovation in ophthalmology, addressing a large unmet need. The company's success hinges on clinical proof-of-concept demonstrating efficacy and safety comparable to or better than existing injectable therapies. With a strong scientific foundation and a clear value proposition, Exonate is positioned for potential growth pending clinical data readouts, regulatory milestones, or strategic partnerships. However, given limited public information on financials and specific timelines, near-term visibility is moderate, and the company faces typical early-stage development risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 clinical data readout for lead SRPK1 inhibitor in diabetic macular edema30% success
• 2026Series A or B financing round to support clinical development50% success
• 2026Strategic partnership for development and commercialization rights outside the UK25% success